The FDA has designated Click Therapeutics' CT-132, a digital therapeutic that is recommended for the treatment of episodic migraine, as a game-changing product.
CT-132 is currently being developed as an adjunctive preventive therapy for episodic migraine in individuals who are 18 years of age and older.
The company claims that its Migraine Advisory Board actively supports the CT-132 initiative.
Click has completed or begun three clinical studies on CT-132 using its patented Click Neurobehavioral Intervention (CNI) Platform.
When completed, the data will support the product's submission of regulatory information to the FDA.